Compare · ECOR vs LIVN
ECOR vs LIVN
Side-by-side comparison of electroCore Inc. (ECOR) and LivaNova PLC (LIVN): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ECOR and LIVN operate in Biotechnology: Electromedical & Electrotherapeutic Apparatus (Health Care), so they compete in similar markets.
- LIVN is the larger of the two at $4.37B, about 51.2x ECOR ($85.4M).
- Both names hit the wire about 7 times in the past 4 weeks.
- LIVN has more recent analyst coverage (20 ratings vs 2 for ECOR).
- Company
- electroCore Inc.
- LivaNova PLC
- Price
- -
- -
- Market cap
- $85.4M
- $4.37B
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2018
- News (4w)
- 7
- 7
- Recent ratings
- 2
- 20
electroCore Inc.
electroCore, Inc., a commercial stage medical device company, engages in the development and commercialization of a range of non-invasive vagus nerve stimulation (nVNS) therapies. The company is developing gammaCore, a prescription-only nVNS therapy for the acute treatment of pain associated with migraine and episodic cluster headache in adults. Its lead product is gammaCore Sapphire, a rechargeable and reloadable handheld delivery system for multi-year use prescribed on a monthly basis. The company was founded in 2005 and is headquartered in Rockaway, New Jersey.
LivaNova PLC
LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. It operates in two segments, Cardiovascular (CV) and Neuromodulation (NM). The CV segment develops, produces, and sells cardiopulmonary products, including heart-lung machines, oxygenators, perfusion tubing sets, cannulae, and accessories, as well as related equipment and disposables for autotransfusion and autologous blood washing for neonatal, pediatric, and adult patients. It also provides surgical tissue and mechanical valve replacements, and repair products for damaged or diseased heart valves, such as self-anchoring tissue heart, tissue heart, and mechanical heart valves, as well as heart valve repair products; and temporary extracorporeal cardiopulmonary life support solutions for critically ill patients. The NM segment designs, develops, and markets VNS Therapy System, an implantable device that delivers vagus nerve stimulation (VNS) therapy for the treatment of drug-resistant epilepsy, difficult-to-treat depression, and obstructive sleep apnea. It is also involved in the development and clinical testing of the VITARIA System for treating heart failure through VNS. The company serves perfusionists, neurologists, neurosurgeons, and other physicians, as well as hospitals, other medical institutions, and healthcare providers. It sells its products through direct sales representatives and independent distributors. The company has a research collaboration with Verily to capture clinical biomarkers of depression. LivaNova PLC was founded in 1987 and is headquartered in London, the United Kingdom.
Latest ECOR
- CFO and Interim President Lev Joshua S. exercised 20,000 shares at a strike of $4.50 and sold $200,120 worth of shares (20,000 units at $10.01) (SEC Form 4)
- electroCore’s Truvaga® Named Best Luxury Biohacking & Longevity Brand in the USA by Luxury Lifestyle Awards
- Director Errico Thomas J. bought $49,272 worth of shares (5,000 units at $9.85), increasing direct ownership by 1% to 343,332 units (SEC Form 4)
- SEC Form 10-Q filed by electroCore Inc.
- electroCore Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- electroCore Announces Second Quarter 2026 Financial Results
- electroCore to Participate in Upcoming Investor Conferences
- electroCore to Announce Second Quarter June 30, 2026, Financial Results on Thursday, August 6, 2026
- SEC Form DEF 14A filed by electroCore Inc.
- New Review Examines Anatomical and Methodological Differences Between Auricular and Cervical Vagus Nerve Stimulation
Latest LIVN
- Chief Innovation Officer Tezel Ahmet exercised 12,692 units of Ordinary Shares at a strike of $52.68, returned $668,740 worth of Ordinary Shares to the company (8,589 units at $77.86), covered exercise/tax liability with 1,428 units of Ordinary Shares and sold $207,942 worth of Ordinary Shares (2,675 units at $77.74) (SEC Form 4)
- SEC Form SCHEDULE 13G filed by LivaNova PLC
- SEC Form IRANNOTICE filed by LivaNova PLC
- SEC Form 10-Q filed by LivaNova PLC
- SEC Form 3 filed by new insider Folli Stefano
- LivaNova PLC filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- LivaNova Reports Second-Quarter 2026 Results; Raises Full-Year 2026 Revenue and Adjusted Diluted EPS Guidance
- LivaNova to Announce Second-Quarter 2026 Results
- Director Wilver Peter M covered exercise/tax liability with 486 units of Ordinary Shares and converted options into 4,042 units of Ordinary Shares, increasing direct ownership by 53% to 10,294 units (SEC Form 4)
- Chief Innovation Officer Tezel Ahmet converted options into 2,965 units of Ordinary Shares and covered exercise/tax liability with 1,032 units of Ordinary Shares, increasing direct ownership by 46% to 6,090 units (SEC Form 4)